Project Grant R43AI096641

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $709,019 to the Benaroya Research Institute at Virginia Mason in Seattle, WA to conduct research on the role of the FOXP3 isoform in regulating autoantibody production and the development of systemic lupus erythematosus (SLE). The key objectives are to: 1) determine how the FOXP3 exon 2 isoform impacts germinal...

The University of Massachusetts Medical School was awarded a $494,929 Project Grant from the National Institute of Allergy and Infectious Diseases to study the role of Toll-like receptors, type II interferon and type III interferon in a murine model of autoinflammation. The grant will support research exploring the effector mechanisms responsible for inducing and regulating cutaneous lupus using genetically modified mice with discriminating mutations. Specifically, the researchers will use...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research conducted by the Scripps Research Institute to identify small molecule compounds that can selectively induce the differentiation of functional regulatory T cells (Tregs). The $417,984 award, effective March 7, 2025 through February 28, 2026, aims to: 1) determine the mechanism of action and optimize the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $235,500.00 to Rutgers, The State University of New Jersey to develop a Trispecific Killer Cell Engager (TRIKE) that can effectively eliminate pathogenic immune cells in patients with Systemic Lupus Erythematosus (SLE). The goal is to create a novel immunotherapeutic approach that leverages high-affinity natural killer (NK) cell engagement to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, WA. The funding supports research to develop an engineered immunoglobulin G (IgG) protease enzyme for the treatment of immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. The key objectives are...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $166,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of Southern California (USC). The objective of this 2-year project is to establish a high-throughput drug screening pipeline to identify selective inhibitors of pro-autoimmune Th17 cells, while also generating biotinylated clofazimine (CLF) to determine its molecular targets in these cells. This...

This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...

This Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $312,323 to Knoubis Bio Inc. to develop a novel bispecific biologic therapy for rheumatoid arthritis (RA). The project aims to target the transmembrane tyrosine phosphatase PTPRS and its extracellular ligand syndecan-4 to reduce synoviocyte invasiveness and inflammatory arthritis, providing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,288,215 to The University of Texas MD Anderson Cancer Center to conduct research on the role of the GRAIL gene in B cell tolerance and B cell-mediated inflammation. The key objectives are to: Determine the molecular mechanisms by which GRAIL regulates B cell tolerance and activation. This will involve identifying the specific targets and...